Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
Want to see ASRT full AI Analyst Report?
ASRT Stock Chart & Stats
$18.02
-$0.03(-3.72%)
At close: 4:00 PM EST
$18.02
-$0.03(-3.72%)
Day’s Range― - ―
52-Week Range$8.56 - $20.45
Previous CloseN/A
Volume363.47K
Average Volume (3M)164.11K
Market Cap
$116.14M
Enterprise Value$145.04M
Total Cash (Recent Filing)$63.41M
Total Debt (Recent Filing)$39.12M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
May 11, 2026EPS Estimate
-2.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding6,445,161
10 Day Avg. Volume232,802
30 Day Avg. Volume164,108
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.62
Price to Sales (P/S)0.49
P/FCF Ratio-2.06
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue1.22
Enterprise Value/Gross Profit1.74
Enterprise Value/Ebitda11.35
Forecast
1Y Price Target
$20.51Price Target Upside13.82% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$103.70M
Bulls Say, Bears Say
Bulls Say
Acquisition ApprovalBoards of directors for both companies unanimously approved the acquisition by Garda, increasing the likelihood of transaction closing and providing a clear cash outcome for shareholders.
Commercialization Focus And LeadershipAnalyst highlights the new CEO's oncology experience and a concentrated commercialization strategy for Rolvedon, which supports expectations for accelerated sales, improved net pricing, and expansion into new accounts.
Product Competitive Advantage And MarginsRolvedon's leading position in clinic channels and same-day dosing give a competitive edge that can sustain market share and contribute to margin improvement as product mix strengthens.
Bears Say
Contingent Milestone Value SkepticismContingent payments tied to Sprix milestones are viewed as unlikely to add meaningful value given the product's limited scale and exposure to patent challenges.
Limited Public Market UpsideAnalyst downgraded the shares to Hold, noting that the Garda acquisition limits remaining public market upside and reduces the chance of further public appreciation.
Non-core Asset Sales And Revenue ReductionSale of non-core legacy products at low valuation multiples removes previously contributing revenue streams and lowers near-term top-line prospects for the company.
Assertio Therapeutics News
ASRT FAQ
What was Assertio Therapeutics Inc’s price range in the past 12 months?
Assertio Therapeutics Inc lowest stock price was $8.56 and its highest was $20.45 in the past 12 months.
What is Assertio Therapeutics Inc’s market cap?
Assertio Therapeutics Inc’s market cap is $116.14M.
When is Assertio Therapeutics Inc’s upcoming earnings report date?
Assertio Therapeutics Inc’s upcoming earnings report date is May 11, 2026 which is in 24 days.
How were Assertio Therapeutics Inc’s earnings last quarter?
Assertio Therapeutics Inc released its earnings results on Mar 16, 2026. The company reported -$1.86 earnings per share for the quarter, beating the consensus estimate of -$3.122 by $1.262.
Is Assertio Therapeutics Inc overvalued?
According to Wall Street analysts Assertio Therapeutics Inc’s price is currently Undervalued.
Does Assertio Therapeutics Inc pay dividends?
Assertio Therapeutics Inc does not currently pay dividends.
What is Assertio Therapeutics Inc’s EPS estimate?
Assertio Therapeutics Inc’s EPS estimate is -2.1.
How many shares outstanding does Assertio Therapeutics Inc have?
Assertio Therapeutics Inc has 6,445,161 shares outstanding.
What happened to Assertio Therapeutics Inc’s price movement after its last earnings report?
Assertio Therapeutics Inc reported an EPS of -$1.86 in its last earnings report, beating expectations of -$3.122. Following the earnings report the stock price went up 6.202%.
Which hedge fund is a major shareholder of Assertio Therapeutics Inc?
Currently, no hedge funds are holding shares in ASRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assertio Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.51 (13.82% Upside)
$20.51 (13.82% Upside)
Blogger Sentiment
Bearish
ASRT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
93.20%
12-Months-Change
Fundamentals
Return on Equity
-29.39%
Trailing 12-Months
Asset Growth
-6.24%
Trailing 12-Months
Company Description
Assertio Therapeutics Inc
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
ASRT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive long-term outlook centered on Robodon: integration is complete, FY2025 results beat guidance, margins and adjusted EBITDA improved year-over-year, and management provided 2026 guidance that anticipates profitability expansion. However, material near-term challenges remain — notably the large Q4 revenue decline and negative Q4 adjusted EBITDA driven by a timing-driven sell-in, a significant sequential cash reduction due to working capital, and ongoing erosion risk in legacy products (Indocin) from generic competition. Management frames many negatives as temporary (sell-in timing, working capital) and emphasizes durable improvements (commercial platform, cost reductions, Robodon secular demand). Balancing the substantial positive catalysts and guidance against the short-term execution and cash pressures yields an overall positive outlook conditional on Robodon demand and normalization of working capital.View all ASRT earnings summariesASRT Stock 12 Month Forecast
Average Price Target
$20.51
▲(13.82% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---